Pasar al contenido principal

INGENIERIA METABOLICA Y GENOMICA EN FACTORIAS BACTERIANAS PARA LA OPTIMIZACION DE LA PRODUCCION DE NUTRACEUTICOS DESTINADOS A LOS SECTORES FARMACIA Y ALIMENTACION (INGENIO)

AGL2017-88095-R

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2017
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE OVIEDO

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Repositioning microbial biotechnology against COVID‐19: the case of microbial production of flavonoids

  • Goris, Tobias
  • Pérez-Valero, Álvaro
  • Martínez, Igor
  • Yi, Dong
  • Fernández-Calleja, Luis
  • San León, David
  • Bornscheuer, Uwe T.
  • Magadán-Corpas, Patricia
  • Lombó, Felipe
  • Nogales, Juan
Coronavirus‐related disease 2019 (COVID‐19) became a pandemic in February 2020, and worldwide researchers try to tackle the disease with approved drugs of all kinds, or to develop novel compounds inhibiting viral spreading. Flavonoids, already investigated as antivirals in general, also might bear activities specific for the viral agent causing COVID‐19, SARS‐CoV‐2. Microbial biotechnology and especially synthetic biology may help to produce flavonoids, which are exclusive plant secondary metabolites, at a larger scale or indeed to find novel pharmaceutically active flavonoids. Here, we review the state of the art in (i) antiviral activity of flavonoids specific for coronaviruses and (ii) results derived from computational studies, mostly docking studies mainly inhibiting specific coronaviral proteins such as the 3CL (main) protease, the spike protein or the RNA‐dependent RNA polymerase. In the end, we strive towards a synthetic biology pipeline making the fast and tailored production of valuable antiviral flavonoids possible by applying the last concepts of division of labour through co‐cultivation/microbial community approaches to the DBTL (Design, Build, Test, Learn) principle., This work was supported by the European Union's Horizon 2020 Research and Innovation Programme under Grant Agreement no. 814650 for the project SynBio4Flav, by Principado de Asturias (GRUPIN IDI/2018/000120 and Programa Severo Ochoa PA‐20‐PF‐BP2019‐058), by the Spanish Ministerio de Economía, Industria y Competitividad (AGL2017‐88095‐R) and ‘RobExplode PID2019‐108458RB‐I00’ (AEI /10.13039/501100011033)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Multifunctional SEVA shuttle vectors for actinomycetes and Gram-negative bacteria

  • García‐Gutiérrez, Coral
  • Aparicio, Tomás
  • Torres‐Sánchez, Lucía
  • Martínez‐García, Esteban
  • Lorenzo, Víctor de
  • Villar, Claudio J.
  • Lombó, Felipe
© 2020 The Authors., Actinomycetales, such as the genus Streptomyces, are well‐known cell factories employed to produce a wide variety of secondary metabolites for industrial use. However, not only is the genetic engineering of Streptomyces more complicated and tedious than other model laboratory species, such as Escherichia coli, there is also a considerable lack of genetic tools, hindering its adoption as a common chassis for synthetic biology. In this work, 23 novel shuttle vectors are presented that follow the canonical SEVA (Standard European Vector Architecture) common architecture with the goal of increasing the genetic toolbox repertoire for Streptomyces and other actinomycetes. The ORI module of these plasmids is composed of the combination of two origins of replication, one for Gram‐negative bacteria and the other for Streptomyces, a Gram‐positive bacteria. Origins of replication have been included in the collection for integrative, low‐copy number, and medium‐to‐high‐copy number vectors for Streptomyces. Also, a new selection marker has been developed that confers resistance to apramycin. The functionality of these plasmids was tested via the heterologous expression of GFP and the heterologous production of the plant flavonoid apigenin in Streptomyces albus J1074, with successful results in both cases, therefore expanding the current repertoire of genetic manipulation tools in Streptomyces species., The authors wish to thank the research project AGL2017‐88095‐R (MINECO, Spanish Ministry of Economy and Business), IDI/2018/000120 (Programa de Ayudas a Grupos de Investigación del Principado de Asturias), the European Union's Horizon 2020 Research and Innovation Programme under Grant Agreement no. 814650, and the FET Program 766975 for financial support. The authors thank the Scientific‐Technical Services (University of Oviedo) for their support with confocal microscopy and HPLC‐MS.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Antiproliferative and palliative activity of flavonoids in colorectal cancer

  • Fernández, Javier
  • Silván, Blanca
  • Entrialgo-Cadierno, Rodrigo
  • Villar, Claudio J.
  • Capasso, Raffaele
  • Uranga-Ocio, José Antonio
  • Lombó, Felipe
  • Abalo, Raquel
Flavonoids are plant bioactive compounds of great interest in nutrition and pharmacology, due to their remarkable properties as antioxidant, anti-inflammatory, antibacterial, antifungal and antitumor drugs. More than 5000 different flavonoids exist in nature, with a huge structural diversity and a plethora of interesting pharmacological properties. In this work, five flavonoids were tested for their potential use as antitumor drugs against three CRC cell lines (HCT116, HT-29 and T84). These cell lines represent three different stages of this tumor, one of which is metastatic. Xanthohumol showed the best antitumor activity on the three cancer cell lines, even better than that of the clinical drug 5-fluorouracil (5-FU), although no synergistic effect was observed in the combination therapy with this drug. On the other hand, apigenin and luteolin displayed slightly lower antitumor activities on these cancer cell lines but showed a synergistic effect in combination with 5-FU in the case of HTC116, which is of potential clinical interest. Furthermore, a literature review highlighted that these flavonoids show very interesting palliative effects on clinical symptoms such as diarrhea, mucositis, neuropathic pain and others often associated with the chemotherapy treatment of CRC. Flavonoids could provide a double effect for the combination treatment, potentiating the antitumor effect of 5-FU, and simultaneously, preventing important side effects of 5-FU chemotherapy., This research was funded by Proyectos I+D+I, del Programa Estatal de Investigación, Desarrollo e Innovación Orientada a los Retos de la Sociedad, from Ministerio de Ciencia, Innovación y Universidades of Spain (AGL2017-88095-R; PID2019-111510RBI00); the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement no. 814650 for the project SynBio4Flav; Grupo Español de Motilidad Digestiva (Beca Allergan, 2017 call); Universidad Rey Juan Carlos, Spain (funds to the High Performance Research Group in Physiopathology and Pharmacology of the Digestive System, NeuGut URJC); and the Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Spain (grant to JF from Contratos Postdoctorales Intramuralespara Grupos de Investigación)